Dr. Catherine Labbé, Institut universitaire de cardiologie et de pneumologie de Québec – Université Laval, Québec, QC

Lung cancer treatment is rapidly evolving with many advances in molecular testing, the development of next-generation tyrosine kinase inhibitors, and the continued broad study of immunotherapy in new settings and potential combinations. The goal of this presentation will be to review recent pivotal and practice-changing trials and to discuss current guidelines for the management of NSCLC and SCLC.

Learning Objectives
At the end of this presentation, attendees will be able to:

  • Review the role and benefit of tyrosine kinase inhibitors in various settings;
  • Review the role and benefit of immunotherapy in NSCLC and SCLC; and
  • Choose appropriate therapy based on stage of disease and molecular testing.

CanMEDs Competencies addressed:
Health Advocate, Medical Expert, Scholar